MeVis Medical Solutions AG (M3V:XETRA) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the MeVis Medical Solutions AG stock forecast from 0 analysts, the average analyst target price for MeVis Medical Solutions AG is not available over the next 12 months. MeVis Medical Solutions AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of MeVis Medical Solutions AG is Slightly Bullish , which is based on 11 positive signals and 5 negative signals. At the last closing, MeVis Medical Solutions AG’s stock price was EUR 25.60. MeVis Medical Solutions AG’s stock price has changed by +1.59% over the past week, +2.40% over the past month and -22.42% over the last year.
No recent analyst target price found for MeVis Medical Solutions AG
No recent average analyst rating found for MeVis Medical Solutions AG
Company Overview MeVis Medical Solutions AG
MeVis Medical Solutions AG develops, markets, and sells software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. The company also offers three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians, as well as internet-based special applications in teleradiology. In addition, it develops and sells software licenses; and provides services for technical visualization and online training. The company was incorporated in 1997 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Deutschland AG. Address: Caroline-Herschel-Str. 1, Bremen, Germany, 28359 Read Less
MeVis Medical Solutions AG develops, markets, and sells software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses ...Read More
Frequently Asked Questions About MeVis Medical Solutions AG (M3V:XETRA) Stock
Stock Target Advisor's fundamental analysis for MeVis Medical Solutions AG's stock is Slightly Bullish .
M3V:XETRA stock's dividend yield is 3.74%.
Our analysis grades M3V:XETRA stock's dividend yield at C. This means that M3V:XETRA stock's dividend yield is above 75% of the stocks in the Health Information Services sector in the XETRA exchange.
Based on this M3V:XETRA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on M3V:XETRA's stock to indicate what its average analyst target is.
M3V:XETRA stock's Price/Earning ratio is 9.48.
Our analysis grades M3V:XETRA stock's Price / Earning ratio at C. This means that M3V:XETRA stock's Price/Earning ratio is above 25% of the stocks in the Health Information Services sector in the XETRA exchange.
Based on this M3V:XETRA may be undervalued for its sector.
The last closing price of M3V:XETRA's stock was EUR 25.60.
The most recent market capitalization for M3V:XETRA is EUR 0.05B.
Unfortunately we do not have enough analyst data on M3V:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MeVis Medical Solutions AG's stock.
As per our most recent records MeVis Medical Solutions AG has 101 Employees.
MeVis Medical Solutions AG's registered address is Caroline-Herschel-Str. 1, Bremen, Germany, 28359.
You can get more information about it from MeVis Medical Solutions AG's website at https://www.mevis.de.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for M3V:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
